TLX News: Scintimun® Commercialization Partnership with Curium Pharma - 13th Jan 2025, 4:08pm

[annb0t]

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic radiopharmaceutical used for infection imaging[1]. The agreement also includes a strategic contract manufacturing agreement appointing Curium ...

>>> Read more: Scintimun® Commercialization Partnership with Curium Pharma